1. Tan AC, Ashley DM, Lopez GY, Malinzak M, Friedman HS, Khasraw M: Management of glioblastoma: State of the art and future directions. CA Cancer J Clin 2020, 70:299-312.
2. Yan W, Zhang W, You G, Zhang J, Han L, Bao Z, Wang Y, Liu Y, Jiang C, Kang C, et al: Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group. Neuro Oncol 2012, 14:1432-1440.
3. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17:98-110.
4. Chai R, Li G, Liu Y, Zhang K, Zhao Z, Wu F, Chang Y, Pang B, Li J, Li Y, et al: Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma. Cancer Biol Med 2021, 18:272-282.
5. Nicolaidis S: Biomarkers of glioblastoma multiforme. Metabolism 2015, 64:S22-27.
6. Linhares P, Carvalho B, Vaz R, Costa BM: Glioblastoma: Is There Any Blood Biomarker with True Clinical Relevance? Int J Mol Sci 2020, 21.
7. Fu M, Hussain A, Dong Y, Fei Y: A retrospective analysis of GSE84010: Cell adhesion molecules might contribute to bevacizumab resistance in glioblastoma. Journal of Clinical Neuroscience 2021, 86:110-115.
8. Bouchart C, Trepant AL, Hein M, Van Gestel D, Demetter P: Prognostic impact of glioblastoma stem cell markers OLIG2 and CCND2. Cancer Med 2020, 9:1069-1078.
9. Liu H, Weng W, Guo R, Zhou J, Xue J, Zhong S, Cheng J, Zhu MX, Pan SJ, Li Y: Olig2 SUMOylation protects against genotoxic damage response by antagonizing p53 gene targeting. Cell Death Differ 2020, 27:3146-3161.
10. Zhang T, Jin Y, Jiang X, Li L, Qi X, Mao Y, Hua D: Clinical and Prognostic Relevance of B7-H3 and Indicators of Glucose Metabolism in Colorectal Cancer. Front Oncol 2020, 10:546110.
11. Lemke D, Pfenning PN, Sahm F, Klein AC, Kempf T, Warnken U, Schnolzer M, Tudoran R, Weller M, Platten M, Wick W: Costimulatory protein 4IgB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness. Clin Cancer Res 2012, 18:105-117.
12. Johnston MJ, Nikolic A, Ninkovic N, Guilhamon P, Cavalli FMG, Seaman S, Zemp FJ, Lee J, Abdelkareem A, Ellestad K, et al: High-resolution structural genomics reveals new therapeutic vulnerabilities in glioblastoma. Genome Res 2019, 29:1211-1222.
13. Zhang H, Zhang J, Li C, Xu H, Dong R, Chen CC, Hua W: Survival Association and Cell Cycle Effects of B7H3 in Neuroblastoma. J Korean Neurosurg Soc 2020, 63:707-716.
14. Kijima N, Kanemura Y: Molecular Classification of Medulloblastoma. Neurol Med Chir (Tokyo) 2016, 56:687-697.
15. Archer TC, Mahoney EL, Pomeroy SL: Medulloblastoma: Molecular Classification-Based Personal Therapeutics. Neurotherapeutics 2017, 14:265-273.
16. Hui AB, Lo KW, Yin XL, Poon WS, Ng HK: Detection of multiple gene amplifications in glioblastoma multiforme using array-based comparative genomic hybridization. Lab Invest 2001, 81:717-723.
17. Guo XX, Su J, He XF: A 4-gene panel predicting the survival of patients with glioblastoma. J Cell Biochem 2019, 120:16037-16043.
18. Breiman L: Random Forests. Machine Learning 2001, 45.
19. Sarica A, Cerasa A, Quattrone A: Random Forest Algorithm for the Classification of Neuroimaging Data in Alzheimer's Disease: A Systematic Review. Front Aging Neurosci 2017, 9:329.
20. Castaneda-Vega S, Katiyar P, Russo F, Patzwaldt K, Schnabel L, Mathes S, Hempel J-M, Kohlhofer U, Gonzalez-Menendez I, Quintanilla-Martinez L, et al: Machine learning identifies stroke features between species. Theranostics 2021, 11:3017-3034.
21. Wang X, Yu B, Ma A, Chen C, Liu B, Ma Q: Protein-protein interaction sites prediction by ensemble random forests with synthetic minority oversampling technique. Bioinformatics 2019, 35:2395-2402.
22. Langfelder P, Horvath S: WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 2008, 9:559.
23. Yu G, Wang LG, Han Y, He QY: clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 2012, 16:284-287.
24. Kanehisa M, Goto S: KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Research 2000, 28:27-30.
25. Harris MA, Clark J, Ireland A, Lomax J, Ashburner M, Foulger R, Eilbeck K, Lewis S, Marshall B, Mungall C, et al: The Gene Ontology (GO) database and informatics resource. Nucleic Acids Research 2004, 32:D258-D261.
26. Osborne JD, Flatow J, Holko M, Lin SM, Kibbe WA, Zhu LJ, Danila MI, Feng G, Chisholm RL: Annotating the human genome with Disease Ontology. BMC Genomics 2009, 10 Suppl 1:S6.
27. Crisman TJ, Zelaya I, Laks DR, Zhao Y, Kawaguchi R, Gao F, Kornblum HI, Coppola G: Identification of an Efficient Gene Expression Panel for Glioblastoma Classification. PLoS One 2016, 11:e0164649.
28. Kupp R, Shtayer L, Tien AC, Szeto E, Sanai N, Rowitch DH, Mehta S: Lineage-Restricted OLIG2-RTK Signaling Governs the Molecular Subtype of Glioma Stem-like Cells. Cell Rep 2016, 16:2838-2845.
29. Zhang M, Zhang H, Fu M, Zhang J, Zhang C, Lv Y, Fan F, Zhang J, Xu H, Ye D, et al: The Inhibition of B7H3 by 2-HG Accumulation Is Associated With Downregulation of VEGFA in IDH Mutated Gliomas. Frontiers in Cell and Developmental Biology 2021, 9.
30. Zhou Z, Luther N, Ibrahim GM, Hawkins C, Vibhakar R, Handler MH, Souweidane MM: B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma. J Neurooncol 2013, 111:257-264.
31. Zhang J, Wang J, Marzese DM, Wang X, Yang Z, Li C, Zhang H, Zhang J, Chen CC, Kelly DF, et al: B7H3 regulates differentiation and serves as a potential biomarker and theranostic target for human glioblastoma. Lab Invest 2019, 99:1117-1129.
32. Karsy M, Guan J, Cohen AL, Jensen RL, Colman H: New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M. Curr Neurol Neurosci Rep 2017, 17:19.
33. Wang Z, Sun D, Chen YJ, Xie X, Shi Y, Tabar V, Brennan CW, Bale TA, Jayewickreme CD, Laks DR, et al: Cell Lineage-Based Stratification for Glioblastoma. Cancer Cell 2020, 38:366-379 e368.